Vonoprazan-based Versus Esomeprazole-based Triple Therapy for Helicobacter Pylori Eradication
Recruiting
Phase 4
Interventional Study
Helicobacter Pylori Infection
Dyspepsia
Peptic Ulcer Disease
Helicobacter Pylori
H Pylori
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
Prior Safety Data
This treatment has already been tested in at least one earlier human trial.
At a Glance
- Age
- 18 and older
- Sex
- Any
- Trial phase
- Phase 4
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 80 (estimated)
- Sponsor
- Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
The goal of this clinical trial is to compare the efficacy and safety of vonoprazan-based levofloxacin-containing triple therapy with esomeprazole-based levofloxacin-containing triple therapy for eradication of Helicobacter pylori infection in adults with dyspepsia.
The main questions it aims to answer are whether vonoprazan-based triple therapy achieves a higher eradication rate of H. pylori, wh…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
1. Age ≥ 18 years
2. Dyspeptic patients with positive for both rapid urease test and stool antigen test
3. Patients giving written informed consent
Exclusion Criteria:
1. Treatment with a proton pump inhibitor, H2-receptor antagonist within the last 2 weeks, prior to the study…
Contacts